- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy (SMA)
- Meeting Date: July 2026
Onasemnogene abeparvovec – July 2026
- 1 vial solution for intrathecal injection 1.2 x 1014 vector genomes per mL, 3 mL
Public Summary Documents
Last updated
13 November 2026
